Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg
This article was originally published in The Tan Sheet
The FDA commissioner tells a House subcommittee that a job candidate questioned whether the “uncertainty” of government work was worth leaving academia, creating another hurdle for agency efforts to fill senior leadership positions.
You may also be interested in...
Daniel Fabricant will be the CEO of NPA, and leave his post as director of FDA’s Division of Dietary Supplement Programs, the association announced April 8.
The federal shutdown interrupts FDA’s increasing enforcement against firms marketing violative supplement products in addition to slowing drug application evaluations and facility inspections. FDA would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”
Sequester Travel: Halved FDA Budget Limits Opportunities For Scientists, Impacts Senior Officials Too
Analysis of meetings in FDA’s public calendar indicates Commissioner Hamburg, other senior leaders continue to attend meetings throughout the U.S. and overseas; stakeholders worry sequester-induced travel cuts prevent rank-and-file scientists from attending helpful events.